罗沙司他治疗慢性肾脏病维持性血液透析患者的临床效果及对铁代谢、炎症因子的影响

Abstract
Figure/Table
References (15)
Related Citation (15)

Download: PDF (0 KB) HTML (33 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the clinical efficacy of Losartan in the treatment of maintenance hemodialysis(MHD)patients with chronic kidney disease(CKD)and its effect on iron metabolism and inflammatory factors.Methods A total of 50 patients with CKD who received maintenance hemodialysis in Xiaolan people′s Hospital of Zhongshan City from June 2019 to June 2020 were selected as the research objects.They were randomly divided into the treatment group and the control group,with 25 cases in each group.The treatment group was treated with Losartan,while the control group was treated with conventional renal anemia The changes of C-reactive protein(CRP),interleukin-6(IL-6),ferritin(SF)and transferin saturation(TSAT)were observed.Results After 3 months of treatment,the total clinical effective rate of the treatment group was higher than that of the control group,and the difference was statistically significant(P<0.05).There were no significant differences in CRP,IL-6,TSAT and SF between the two groups before treatment and one month after treatment(P>0.05).After 2 and 3 months of treatment,CRP,IL-6 and SF in the treatment group were lower than those in the control group,and TSAT was higher than that in the control group,with statistical significances(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion Losartan in the treatment of maintenance hemodialysis patients with CKD can effectively improve the symptoms of anemia,relieve the micro inflammatory state,and has high safety.

Key words： Losartan Maintenance hemodialysis Anemia C-reactive protein Interleukin-6 Ferritin Transferrin saturation

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHANG Wen-bin
	CHI Xiang-geng
	CHEN Yan-zhuan
	XUAN Xing-hua
	CAI Qi

Cite this article:

ZHANG Wen-bin,CHI Xiang-geng,CHEN Yan-zhuan, et al. Clinical effect of Losartan on maintenance hemodialysis and its effect on iron metabolism and inflammatory factors[J]. 中国当代医药, 2021, 28(27): 69-72.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2021/V28/I27/69

[1]	陈楠.罗沙司他在慢性肾脏病患者肾性贫血治疗中的应用[J].中华内科杂志，2019，58（12）：919-920.
[2]	王睿，胡洪涛，胡双，等.罗沙司他治疗慢性肾脏病贫血患者的meta 分析[J].临床肾脏病杂志，2019，19（12）：871-876.
[3]	周雅萍，李凯.治疗肾性贫血新药罗沙司他[J].药物评价研究，2018，41（9）：1743-1748.
[4]	郑光毅，常晓东，高巍，等.罗沙司他联合免疫抑制剂治疗尿毒症合并纯红细胞再生障碍性贫血一例[J].中华肾脏病杂志，2021，37（1）：57-58.
[5]	刘云，刘荣荣，周道远，等.多糖铁复合物治疗维持性血液透析贫血患者的临床研究[J].中国医师杂志，2020，22（6）：847-851.
[6]	中华医学会肾脏病学分会肾性贫血诊断和治疗共识专家组.肾性贫血诊断与治疗中国专家共识（2018 修订版）[J].中华肾脏病杂志，2018，34（11）：860.
[7]	张之南，沈悌.血液病诊断及疗效标准[M].第3 版.北京：科学出版社，2007：245.
[8]	贺晓瑛，潘兴泉，李家国，等.治疗肾性贫血新药——roxadustat[J].临床药物治疗杂志，2018，16（8）：1-3.
[9]	李宏彬，梁军，马强.罗沙司他胶囊与重组人促红素治疗肾性贫血的效果及预后比较[J].中国医药导报，2020，17（8）：178-181.
[10]	孙艳玲，谢华，康喆，等.罗沙司他治疗初始血液透析患者肾性贫血20 例疗效研究[J].中国实用内科杂志，2020，40（11）：68-72.
[11]	甘红兵，丁嘉祥，任晓英，等.罗沙司他治疗维持性腹膜透析患者贫血疗效观察[J].中国实用内科杂志，2020，40（11）：63-67.
[12]	贾琳，陈文莉，石晶，等.维持性血液透析患者慢性牙周疾病与营养不良-炎症复合性综合征相关性的研究[J].临床肾脏病杂志，2019，19（6）：30-34.
[13]	甘良英.罗沙司他治疗血液透析患者重症感染后贫血1 例报告[J].中国实用内科杂志，2020，40（11）：78-80.
[14]	张丛笑，史丹阳，金晓宇，等.罗沙司他治疗初始透析患者肾性贫血1 例报告[J].中国实用内科杂志，2020，40（11）：92-94.
[15]	王敏敏，叶彬娴，陈王芳，等.单中心腹膜透析患者应用罗沙司他治疗肾性贫血22 例疗效观察[J].中国实用内科杂志，2020，40（11）：52-57.